Paris (France), 30 September 2008
FDA’s first-cycle review of Dysport® to be completed by year-end: US launch of Dysport® on track
Ipsen (Euronext; IPN) today announced that the U.S. Food and Drug Administration (FDA) provided notification that the Prescription Drug User Fee Act (PDUFA) action date for Dysport® (botulinum toxin of type A) Biologics License Application (BLA) for the treatment of patients with cervical dystonia has been extended to no later than 28 December 2008. This regulatory decision will not impact the anticipated company launch plan timing.
Ipsen (Euronext; IPN) today announced that the U.S. Food and Drug Administration (FDA) provided notification that the Prescription Drug User Fee Act (PDUFA) action date for Dysport® (botulinum toxin of type A) Biologics License Application (BLA) for the treatment of patients with cervical dystonia has been extended to no later than 28 December 2008. This regulatory decision will not impact the anticipated company launch plan timing.
Paris (France), 30 September 2008
“Cell Shape and Polarity: Lymphocytes and Beyond”, the fifth meeting in the “Emergence & Convergence” series jointly organised by Nature Immunology, Nature Cell Biology and La Fondation IPSEN
La Fondation IPSEN and Nature Publishing Group share the same desire to help new scientific knowledge emerge and facilitate the exchange of the most promising ideas from a variety of different research areas.
La Fondation IPSEN and Nature Publishing Group share the same desire to help new scientific knowledge emerge and facilitate the exchange of the most promising ideas from a variety of different research areas.
Paris (France), 25 September 2008
Ipsen announces the filing of Decapeptyl® 6-month formulation for the treatment of locally advanced or metastatic prostate cancer in Europe
The filing of the new Decapeptyl® 6-month formulation is in accordance with Ipsen’s regulatory timeline
The filing of the new Decapeptyl® 6-month formulation is in accordance with Ipsen’s regulatory timeline
